The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice

Journal of Clinical Investigation

Volumn 119, Issue 3, 2009, Pages 595-610

  Greenshields, Kay N ^a   Halstead, Susan K ^a   Zitman, Femke M P ^b   Rinaldi, Simon ^a   Brennan, Kathryn M ^a   O'Leary, Colin ^a   Chamberlain, Luke H ^a   Easton, Alistair ^a   Roxburgh, Jennifer ^a   Pediani, John ^a   Furukawa, Koichi ^c   Furukawa, Keiko ^c   Goodyear, Carl S ^a   Plomp, Jaap J ^b   Willison, Hugh J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE GM1 ANTIBODY; GLYCOLIPID; MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; SIALIC ACID; SIALIDASE; AUTOANTIBODY; GANGLIOSIDE GM1; RAN PROTEIN; RANGNRF PROTEIN, MOUSE;

ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; FEMALE; FREEZING; HUMAN; IMMUNOASSAY; MALE; MEMBRANE STRUCTURE; MOUSE; NERVE CELL MEMBRANE; NERVE ENDING; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DOMAIN; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; ANIMAL; IMMUNOLOGY; MOTONEURON; NEUROMUSCULAR SYNAPSE; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AXONS; G(M1) GANGLIOSIDE; GLYCOLIPIDS; HUMANS; MICE; MOTOR NEURONS; NERVE ENDINGS; NEUROMUSCULAR JUNCTION; OLIGOSACCHARIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; RAN GTP-BINDING PROTEIN; SYNAPTIC TRANSMISSION;

EID: 65649088657     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37338     Document Type: Article

References (58)

1. Sandhoff, K., and Kolter, T. 2003. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358:847-861.
2. Simons, K., and Ikonen, E. 1997. Functional rafts in cell membranes. Nature. 387:569-572.
3. Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature. 446:1023-1029.
4. Bullens, R.W., et al. 2002. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 22:6876-6884.
5. Willison, H.J. 2005. Ganglioside complexes: new autoantibody targets in Guillain-Barre syndromes. Nat. Clin. Pract. Neurol. 1:2-3.
6. Crocker, P.R., Paulson, J.C., and Varki, A. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7:255-266.
7. Lencer, W.I., and Tsai, B. 2003. The intracellular voyage of cholera toxin: going retro. Trends Biochem. Sci. 28:639-645.
8. Tsai, B., et al. 2003. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 22:4346-4355.
9. Willison, H.J., and Yuki, N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 125:2591-2625.
10. Yuki, N. 2001. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. 1:29-37.
11. Goodfellow, J.A., et al. 2005. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 25:1620-1628.
12. Kusunoki, S., et al. 1996. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann. Neurol. 39:424-431.
13. Yuki, N., et al. 2001. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 49:712-720.
14. Plomp, J.J., et al. 1999. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann. Neurol. 45:189-199.
15. Bowes, T., et al. 2002. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect. Immun. 70:5008-5018.
16. Yuki, N., et al. 1993. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178:1771-1775.
17. Yuki, N., et al. 2004. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc. Natl. Acad. Sci. U. S. A. 101:11404-11409.
18. Ang, C.W., et al. 2002. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infect. Immun. 70:1202-1208.
19. Arasaki, K., Kusunoki, S., Kudo, N., and Kanazawa, I. 1993. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve. 16:587-593.
20. Buchwald, B., et al. 2007. Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol. Dis. 28:113-121.
21. Nores, G.A., et al. 2007. Anti-GM1 antibodies as a model of the immune response to self-glycans. Biochim. Biophys. Acta. 1780:538-545.
22. Paparounas, K., O'Hanlon, G.M., O'Leary, C.P., Rowan, E.G., and Willison, H.J. 1999. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain. 122:807-816.
23. Schwarz, A., and Futerman, A.H. 1996. The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Biochim. Biophys. Acta. 1286:247-267.
24. Iwamoto, N., et al. 1990. Cell membrane changes in brains manifesting senile plaques: an immunohistochemical study of GM1 membranous ganglioside. Brain Res. 522:152-156.
25. Laev, H., and Mahadik, S.P. 1989. Topography of monosialoganglioside (GM1) in rat brain using monoclonal antibodies. Neurosci. Lett. 102:7-14.
26. Goodyear, C.S., et al. 1999. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze musclenerve preparations. J. Clin. Invest. 104:697-708.
27. Halstead, S.K., et al. 2004. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 127:2109-2123.
28. Yang, L.J., et al. 2006. Sialidase enhances spinal axon outgrowth in vivo. Proc. Natl. Acad. Sci. U. S. A. 103:11057-11062.
29. Townson, K., et al. 2007. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology. 17:294-303.
30. Okada, M., et al. 2002. b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J. Biol. Chem. 277:1633-1636.
31. Merritt, E.A., et al. 1994. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 3:166-175.
32. Court, F.A., et al. 2008. Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. J. Cell. Sci. 121:3901-3911.
33. Goodyear, C.S., et al. 1999. Monoclonal antibodies raised against Guillain Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyse nerve muscle preparations. J. Clin. Invest. 104:697-708.
34. O'Hanlon, G.M., et al. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain. 124:893-906.
35. Boffey, J., et al. 2005. Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. J. Neuroimmunol. 165:92-103.
36. Seyfried, T.N., el Abbadi, M., Ecsedy, J.A., Bai, H.W., and Yohe, H.C. 1996. Influence of host cell infiltration on the glycolipid content of mouse brain tumors. J. Neurochem. 66:2026-2033.
37. Townson, K.H., et al. 2008. Glycosphingolipid depletion in PC12 cells using iminosugars protects neuronal membranes from anti-ganglioside antibody mediated injury. J. Neuroimmunol. 203:33-38.
38. Paterson, G., Wilson, G., Kennedy, P.G.E., and Willison, H.J. 1995. Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse v-region gene usage with extensive somatic mutation. J. Immunol. 155:3049-3059.
39. Ho, T.W., et al. 1997. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 48:717-724.
40. Susuki, K., et al. 2003. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann. Neurol. 54:383-388.
41. Kuziemko, G.M., Stroh, M., and Stevens, R.C. 1996. Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance. Biochemistry. 35:6375-6384.
42. Paulson, J.C., Blixt, O., and Collins, B.E. 2006. Sweet spots in functional glycomics. Nat. Chem. Biol. 2:238-248.
43. Hakomori, S.I., Teather, C., and Andrews, H. 1968. Organizational difference of cell surface "hematoside" in normal and virally transformed cells. Biochem. Biophys. Res. Commun. 33:563-568.
44. Lloyd, K.O., Gordon, C.M., Thampoe, I.J., and DiBenedetto, C. 1992. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 52:4948-4953.
45. Iwabuchi, K., Handa, K., and Hakomori, S. 1998. Separation of "glycosphingolipid signaling domain" from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. J. Biol. Chem. 273:33766-33773.
46. Hakomori, S.I. 2002. Inaugural article: the glycosynapse. Proc. Natl. Acad. Sci. U. S. A. 99:225-232.
47. Sonnino, S., Mauri, L., Chigorno, V., and Prinetti, A. 2007. Gangliosides as components of lipid membrane domains. Glycobiology. 17:1R-13R.
48. Vyas, A.A., et al. 2002. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc. Natl. Acad. Sci. U. S. A. 99:8412-8417.
49. Lehmann, H.C., et al. 2007. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J. Neurosci. 27:27-34.
50. Kusunoki, S., Hitoshi, S., Kaida, K., Arita, M., and Kanazawa, I. 1999. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann. Neurol. 45:400-403.
51. Kaida, K., et al. 2008. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome. Neurology. 71:196-201.
52. Kaida, K., et al. 2004. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann. Neurol. 56:567-571.
53. Kaida, K.I., et al. 2006. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry. 77:1043-1046.
54. Aspinall, G.O., et al. 1994. Lipopolysaccharides from Campylobacter-jejuni associated with Guillain-Barre-syndrome patients mimic human gangliosides in structure. Infect. Immun. 62:2122-2125.
55. Takamiya, K., et al. 1996. Mice with disrupted GM2/ GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc. Natl. Acad. Sci. U. S. A. 93:10662-10667.
56. Chamberlain, L.H., Burgoyne, R.D., and Gould, G.W. 2001. SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc. Natl. Acad. Sci. U. S. A. 98:5619-5624.
57. Willison, H.J., et al. 1999. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur. J. Neurol. 6:71-77.
58. Kanter, J.L., et al. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12:138-143.